Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAVAL-1 phase 2 study of nanatinostat plus valganciclovir in relapsed or refractory EBV-positive lymphomas
MOH_2023-08-20_012756Phase 2Completed
- Sponsor
- .Viracta Therapeutics, Inc
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of nanatinostat and valganciclovir in Epstein-Barr virus-positive diffuse large B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), extranodal natural killer/T-cell lymphoma (ENKTL) and 5 more (8 arms), sponsored by .Viracta Therapeutics, Inc. Started Aug 2023; status: completed.
02
Drugs
nanatinostatvalganciclovir
03
Conditions
Epstein-Barr virus-positive diffuse large B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)extranodal natural killer/T-cell lymphoma (ENKTL)peripheral T-cell lymphoma (PTCL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on MOH_2023-08-20_012756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-08-20_012756.